HOPA's Practice Outcomes and Professional Benchmarking Committee (POPBC) conducted a multi-organization, voluntary survey of HOPA members between March of 2021 and January of 2022. The purpose was to better understand the landscape of oncology pharmacy at healthcare organizations throughout the United States.

The research examined: institutional description, job function, staffing, and training/certification. Data were evaluated using descriptive statistics. The analysis found that as the number of patients with cancer rises, the oncology workforce must grow. The current oncology pharmacy practice landscape can serve as a foundation for future research, metrics, and benchmarks.

This research was published in the Journal of Oncology Pharmacy Practice.

Authors: Shawn P Griffin, Jessie R Signorelli, Aubrey Lasko, Benjamin J Andrick, David Doan, Shannon Hough, Grazyna Riebandt, and Stephen Harnicar

Read the paper

Related Articles

Read all latest news Right Pointing Arrow
medical illustration of inflamation from osteoporosis

Late-Breaking HOPA News: Severe Hypocalcemia in Patients with Advanced Chronic Kidney Disease on Denosumab Therapy

April 01, 2024

Originally approved for the treatment of osteoporosis in postmenopausal women at high risk for fractures, denosumab is now frequently used in the management of hypercalcemia of malignancy and to decrease skeletal-related events for certain cancer patients

Late-Breaking HOPA News: T-cell Malignancies with CAR T-cell therapy

March 27, 2024

In November 2023, the FDA announced their investigation of reports of T-cell lymphomas from clinical trials and post-marketing adverse event data sources for CAR T-cell immunotherapies. In January 2024, the FDA issued Safety Labeling Change notification.

Pharmacist’s Application to Practice: Niraparib and Abiraterone Acetate (Akeega™)

November 12, 2023

Mallori Anderson, PharmD, PGY2 and Christine Barrett, PharmD, BCOP, from the Mary Babb Randolph Cancer Center write about Akeega™